IDEXX Laboratories, Inc.

IDEXX Laboratories (NASDAQ: IDXX) executives highlighted the company's diagnostic innovation pipeline, recurring-revenue growth and commercial investments during the Morgan Stanley Global Healthcare Conference, while reaffirming confidence in its long-term growth framework despite continued pressure on veterinary office visits. Chief Executive Officer Mike Erickson said the company had an "exceptional" second quarter and a strong start to

IDEXX Laboratories (NASDAQ: IDXX) executives reiterated the company's long-term growth framework at the Morgan Stanley Global Healthcare Conference, citing demand for veterinary diagnostics, product innovation, commercial investments and recurring-revenue economics as key drivers. Chief Executive Officer Mike Erickson said IDEXX had an "exceptional Q2" and a strong start to the year, prompting the company to raise

IDEXX Laboratories NASDAQ: IDXX executives highlighted the company's diagnostic innovation pipeline, recurring-revenue growth and commercial investments during the Morgan Stanley Global Healthcare Conference, while reaffirming confidence in its long-term growth framework despite continued pressure on veterinary office visits.

IDEXX Laboratories NASDAQ: IDXX executives reiterated the company's long-term growth framework at the Morgan Stanley Global Healthcare Conference, citing demand for veterinary diagnostics, product innovation, commercial investments and recurring-revenue economics as key drivers.